Page last updated: 2024-09-03

cp 122288 and Neurogenic Inflammation

cp 122288 has been researched along with Neurogenic Inflammation in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Christianssen, I; Diener, HC; Ellis, P; Ferrari, MD; Hettiarachchi, J; Kleinermans, D; Kok, JG; Olesen, J; Poole, PH; Roon, KI1
Hargreaves, RJ; Williamson, DJ1

Reviews

1 review(s) available for cp 122288 and Neurogenic Inflammation

ArticleYear
Neurogenic inflammation in the context of migraine.
    Microscopy research and technique, 2001, May-01, Volume: 53, Issue:3

    Topics: Animals; Blood Proteins; Bosentan; Calcitonin Gene-Related Peptide; Capillary Permeability; Dihydroergotamine; Dura Mater; Humans; Migraine Disorders; Narcotics; Neurogenic Inflammation; Neurokinin-1 Receptor Antagonists; Pyrrolidines; Receptor, Serotonin, 5-HT1D; Receptor, Serotonin, 5-HT1F; Receptors, Neurokinin-1; Receptors, Serotonin; Serotonin Receptor Agonists; Skull; Sulfonamides; Sumatriptan; Trigeminal Nerve; Vasoconstrictor Agents; Vasodilation

2001

Trials

1 trial(s) available for cp 122288 and Neurogenic Inflammation

ArticleYear
No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials.
    Annals of neurology, 2000, Volume: 47, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle Aged; Migraine Disorders; Neurogenic Inflammation; Placebos; Pyrrolidines; Serotonin Receptor Agonists; Sumatriptan; Treatment Failure

2000